key: cord-0719298-aifv23fw
authors: Hamdy, Adam; Leonardi, Anthony
title: Superantigens and SARS-CoV-2
date: 2022-03-23
journal: Pathogens
DOI: 10.3390/pathogens11040390
sha: aaea13b8edc5fa914662079fdb9ced0244ac2387
doc_id: 719298
cord_uid: aifv23fw

It has been posited SARS-CoV-2 contains at least one unique superantigen-like motif not found in any other SARS or endemic coronaviruses. Superantigens are potent antigens that can send the immune system into overdrive. SARS-CoV-2 causes many of the biological and clinical consequences of a superantigen, and, in the context of reinfection and waning immunity, it is important to better understand the impact of a widely circulating, airborne pathogen that may be a superantigen, superantigen-like or trigger a superantigenic host response. Urgent research is needed to better understand the long-term risks being taken by governments whose policies enable widespread transmission of a potential superantigenic pathogen, and to more clearly define the vaccination and public health policies needed to protect against the consequences of repeat exposure to the pathogen.

The term superantigen was coined in 1989 [1] and defined proteins that hyperstimulate T cells via the crosslinking of T cell receptors (TCR) with MHC Class II molecules. The definition was expanded following the discovery of B cell superantigens [2] , which hyper-stimulate a large population of B cells without the crosslink. A superantigen is commonly defined as a molecule that has antigen-receptor mediated interactions with over 5% of the lymphocyte pool [3] .

Put simply, superantigens are potent antigens that can send the immune system into overdrive and stimulate up to 30% of the naive T cell pool [4, 5] . Reactions between superantigens and T cells may lead to a number of outcomes, including anergy, inflammation, cytotoxicity, deletion of T-cells and autoimmunity [6] [7] [8] . Superantigens have also been shown to impair post-vaccination memory cell responses to unrelated antigens and antagonize memory cell activation [9] .

The same superantigen can produce a range of host responses. Toxic shock has been shown to develop more severely in individuals who express certain MHC Class II haplotypes which bind specific superantigens, compared with those who expressed haplotypes with lower binding affinity [10] . Responses may also be affected by environmental factors. For example, simultaneous bacterial and viral infections have been shown to increase the effects of superantigens [11] . Superantigens have been shown to impact central nervous system function and are implicated in the development of neurological conditions [12] [13] [14] and cardiovascular dysfunction [15, 16] .

Superantigens have diverse interactions with MHC class II and T-cell receptor molecules, involving a number of different interaction surfaces and stoichiometries [17] [18] [19] . In addition to superantigens, there are superantigen-like proteins that activate lymphocytes using mechanisms that place them outside the superantigen classification [20] . Superantigen-like proteins have been implicated in inducing thrombotic and bleeding complications through platelet activation [21, 22] . SARS-CoV-2 causes many of the biological and clinical consequences of a superantigen, and we believe in the context of reinfection and waning immunity, it is important to better understand the impact of a widely circulating, airborne pathogen that may be a superantigen, superantigen-like or trigger a superantigenic host response.

T lymphocyte activation during dengue infection is thought to contribute to the pathogenesis of dengue hemorrhagic fever (DHF) [ 

Superantigens have differing effects on immature and mature CD4 and CD8 T-cells ( Figure 1 ). Superantigens can deplete thymocytes or immature T-cells, but can hyperstimulate mature, antigen-experienced CD4s and CD8s Chronic exposure to superantigen could continually stimulate T-cells, keeping them in a perpetual state between anergy and hyperstimulation. Furthermore, given naive Tcells can be activated and differentiated by the bystander effect, this could manifest in an observed naive T-cell depletion in the peripheral blood where naive cells home to lymphoid tissues in individuals where new naive T-cells are not being readily generated due to thymic involution [47, 48] . This effect could explain the paucity of naive T-cells in some Long COVID patients [49] . The loss of naive T-cells is a defining metric in immune aging and dysfunction. They help regulate immune responses and have the highest expansive capacity in response to antigens from cancers and infection [50-52].

Superantigens are implicated in the development of autoimmune diseases [53] [54] [55] [56] [57] [58] . T-cell clones that are cross-reactive towards the endogenous host and microbial epitopes may be stimulated and migrate to tissue containing an autoantigen, a mechanism believed to play a role in the pathogenesis of rheumatic fever [59, 60] . Individuals with autoimmune diseases show an increase in such T-cells in affected organs or peripheral blood [5] . Superantigens stimulate autoantibody production by bridging the MHC Class II molecule of B-cells with the TCR on T-cells [61] . Whether deletion or autoimmunity occurs seems to be a function of dose, persistence, host haplotype and severity of cytokine response [62] . Chronic exposure to superantigen could continually stimulate T-cells, keeping them in a perpetual state between anergy and hyperstimulation. Furthermore, given naive T-cells can be activated and differentiated by the bystander effect, this could manifest in an observed naive T-cell depletion in the peripheral blood where naive cells home to lymphoid tissues in individuals where new naive T-cells are not being readily generated due to thymic involution [47, 48] . This effect could explain the paucity of naive T-cells in some Long COVID patients [49] . The loss of naive T-cells is a defining metric in immune aging and dysfunction. They help regulate immune responses and have the highest expansive capacity in response to antigens from cancers and infection [50-52].

Superantigens are implicated in the development of autoimmune diseases [53] [54] [55] [56] [57] [58] . T-cell clones that are cross-reactive towards the endogenous host and microbial epitopes may be stimulated and migrate to tissue containing an autoantigen, a mechanism believed to play a role in the pathogenesis of rheumatic fever [59, 60] . Individuals with autoimmune diseases show an increase in such T-cells in affected organs or peripheral blood [5]. Superantigens stimulate autoantibody production by bridging the MHC Class II molecule of B-cells with the TCR on T-cells [61] . Whether deletion or autoimmunity occurs seems to be a function of dose, persistence, host haplotype and severity of cytokine response [62] .

Persistent subcutaneous exposure to a superantigen has been shown to cause a systemic inflammatory disease mimicking systemic lupus erythematosus (SLE) in mice [63] . Superantigens have been shown to trigger or exacerbate SLE [64] . Interestingly, HERV-E has been implicated in SLE [65, 66] . HERV-E has been found to be upregulated in the bronchoalveolar lavage fluid of COVID-19 patients [67] .

Insulin-dependent diabetes mellitus (IDDM) is a T-cell-mediated autoimmune disease triggered by unknown environmental factors acting on a predisposing genetic background, but there is evidence superantigen-like exposure in the form of HERV-W-env upregulation is implicated in the recruitment of macrophages in the pancreas and beta-cell dysfunction [68] . Antibodies against HERV-W-env precede or overlap with conventional IDDM antibodies in youths who are susceptible to or have the condition [69] .

We note a recent study of SARS-CoV-2 which found immunological dysfunction following mild to moderate infection, including depletion of naive T and B-cells in individuals with Long COVID [49] , and a single cell atlas which also found depletion of naive T-cells and higher levels of apoptotic T-cells in SARS-CoV-2 infection than HIV [70] . Taken together with findings on post-SARS-CoV-2 autoantibodies [71, 72] , presentation of MIS-C [73] , activation and depletion of T-cells [74] and a rise in IDDM [75] , these are suggestive of a superantigen, superantigen-like protein or triggering of a superantigenic host response as a causative agent, and further research is needed into its role and likely long-term effects, particularly since SARS-CoV-2 has been found to persist in the body months after acute infection [76] [77] [78] [79] [80] [81] [82] . SARS-CoV-2's superantigenic characteristics have been implicated in MIS-C [83] . The expansion of T-cells carrying the TRBV11-2 gene, in combination with variable alpha chains, a hallmark of superantigen-mediated T-cell activation, has been reported in several studies of patients with MIS-C [84, 85] .

Brodin offers an energy allocation hypothesis for MIS-C, suggesting a choice in favor of disease tolerance over maximal resistance that means children are more likely to present with mild and even asymptomatic disease but might also be less efficient at viral clearance and, consequently, be more prone to some level of viral persistence and possibly other conditions linked to such viral persistence such as superantigen-mediated immune activation in MIS-C [86] . We question why such SARS-CoV-2's superantigenic characteristics would not be assumed to apply to adults, particularly given the clinical and biological manifestations in all age groups, which reflect known prior differences between responses to superantigen exposure in adults and children. Indeed, MIS-A manifests in adults as a consequence of SARS-CoV-2 infection [87] and rare instances of Kawasaki disease are observed in adults [88, 89] .

The issue of whether SARS-CoV-2 contains a superantigen is not settled, but the evidence is accumulating [90] [91] [92] [93] [94] [95] and SARS-CoV-2 is causing superantigen or superantigenlike clinical presentations and biomarkers. In addition to cytokine storms [96] , T-cell activation and deletion [74] and presentation of MIS-C [73, 97, 98] (similar to Kawasaki disease, a suspected consequence of superantigen exposure [99] ), those infected by SARS-CoV-2 who suffer Long COVID following infection manifest symptoms [100] typically seen in autoimmune conditions such as SLE [101] [102] [103] , and autoantibodies [71] and antinuclear antibodies [72] have been detected in a proportion of such individuals [104] .

In vitro assessments of SARS-CoV-2's superantigen-like region may not capture the full physiological effect on the immune system in vivo. For example, lipopolysaccharide (LPS) can potentiate the SEB superantigen effect [105] , which could have a synergistic effect on T cells following gut inflammation or injury via LPS translocation [106, 107] .

SARS-CoV-2 is known to infect gut epithelial cells [108] , persist in the gut [79, 109, 110] and disrupt tight junctions in bronchial epithelial barriers [111] . Indeed, hospitalized non-survivors of SARS-CoV-2 infection had increased LPS detected in blood [112] . While SARS-CoV-2 may not be canonically superantigenic in vitro, the in vivo consequences may be significant due to other danger and death signals [113] .

With evidence mounting that SARS-CoV-2 reactivates latent viruses such as Epstein-Barr Virus [114] , cytomegalovirus [115, 116] and human endogenous retrovirus [36] , which are associated with superantigen expression [31, 69, [117] [118] [119] , it is important to establish whether SARS-CoV-2 is a superantigen or triggering second-order superantigenic responses in susceptible individuals.

Some countries seem willing to tolerate high levels of infection provided their healthcare systems can cope. This approach is predicated on the belief a level of protective population immunity can be achieved and sustained, and the impact of reinfections will be less severe [120] . If SARS-CoV-2 contains a superantigen, superantigen-like protein or triggers a superantigenic host response, this strategy may prove a grave error. The effect of a superantigen is dependent on dose exposure, genetic predisposition, environmental conditions and immune response [6,7,12,62].

There is evidence the toxic effects of superantigens can be inhibited by specific antibodies but protection conferred seems to depend on antibody titer and exposure dose [121] . Recent evidence of a reduction in MIS-C following vaccination supports the protective role of antibodies in preventing a clinical manifestation of a superantigen or superantigen-like infection [122] ; however, in the context of waning antibody titers seen following vaccination against [123] or infection [124] by SARS-CoV-2, and ongoing evolution of the virus [125] , the impact of repeat exposure may be unpredictable.

Rather than proving beneficial, allowing widespread transmission of SARS-CoV-2 could be detrimental, and the growing population suffering from Long COVID [126] marked by a depletion of naive T-cells [49] may be a warning. Given the adverse impact Kawasaki disease and some autoimmune conditions can have on long-term health and longevity [127, 128] , national strategies that allow widespread transmission of an airborne [129] potentially superantigenic or superantigen-like pathogen that has demonstrated some evidence of persistence and can inflict repeat infections may be misguided.

If SARS-CoV-2 is a superantigen, superantigen-like or triggers a superantigenic host response, the unpredictable nature of a superantigen makes it particularly difficult to assess what will happen to people on repeat exposure and adds to the overall uncertainty around the long-term effects of the virus [130, 131] . Urgent research is needed to confirm or refute the superantigenic nature of SARS-CoV-2, to better understand the long-term risks being taken by governments whose policies enable widespread transmission and to understand whether it is necessary to maintain consistently high levels of neutralizing antibodies to better protect against the consequences of exposure to the pathogen. It is of vital importance to definitively establish whether SARS-CoV-2 is a superantigen, superantigenlike or triggers a superantigenic host response in order to better understand the short and long-term consequences of infection. It should be noted that one of the superantigen-like motifs posited in SARS-CoV-2 is unique, and not found in any other SARS or endemic coronaviruses [83] and that according to longitudinal analysis of SARS-CoV-2, this motif appears highly conserved [132] . [PubMed]

The V Beta-Specific Superantigen Staphylococcal Enterotoxin B: Stimulation of Mature T Cells and Clonal Deletion in Neonatal Mice

Confounding B-Cell Defences: Lessons From a Staphylococcal Superantigen

Selective Expansion of T Cells Expressing V Beta 2 in Toxic Shock Syndrome

B cell superantigens: Possible roles in immunodeficiency and autoimmunity

Superantigens as virulence factors in autoimmunity and immunodeficiency diseases

The structural basis of T-cell activation by superantigens

Rheumatogenic group A streptococci and the return of rheumatic fever

Staphylococcal enterotoxin D functions as a human B-cell superantigen by rescuing VH4-expressing B-cells from apoptosis

Differential effects of staphylococcal toxic shock syndrome toxin 1 on B cell apoptosis

Chronic exposure to staphylococcal superantigen elicits a systemic inflammatory disease mimicking lupus

Superantigen influence in conjunction with cytokine polymorphism potentiates autoimmunity in systemic lupus erythematosus patients

Retroviruses and autoimmunity

Quantitative analyses of messenger RNA of human endogenous retrovirus in patients with systemic lupus erythematosus

Upregulation of Human Endogenous Retroviruses in Bronchoalveolar Lavage Fluid of COVID-19 Patients

An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes

Anti-HERV-WEnv antibodies are correlated with seroreactivity against Mycobacterium avium subsp. paratuberculosis in children and youths at T1D risk

A single-cell atlas reveals shared and distinct immune responses and metabolism during SARS-CoV-2 and HIV-1 infections

Diverse functional autoantibodies in patients with COVID-19

Antinuclear antibodies in COVID 19

SARS-CoV-2 as a superantigen in multisystem inflammatory syndrome in children

Activation or exhaustion of CD8+ T cells in patients with COVID-19

Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic

SARS-CoV-2 infection and persistence throughout the human body and brain

COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses

Evolution of antibody immunity to SARS-CoV-2

SARS-CoV-2 in the Prostate: Immunohistochemical and Ultrastructural Studies. World J. Men's Health 2022, 40, e12

SARS-CoV-2 identified by transmission electron microscopy in lymphoproliferative and ischaemic intestinal lesions of COVID-19 patients with acute abdominal pain: Two case reports

Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection

Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation

TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C

Polyclonal expansion of TCR Vb 21.3+ CD4+ and CD8+ T cells is a hallmark of multisystem inflammatory syndrome in children

SARS-CoV-2 infections in children: Understanding diverse outcomes

Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection-United Kingdom and United States

Kawasaki Disease in Adults

Adult Kawasaki disease in a European patient: A case report and review of the literature

Are superantigens the cause of cytokine storm and viral sepsis in severe COVID-19? Observations and hypothesis

HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children

In silico evidence of superantigenic features in ORF8 protein from COVID-19. bioRxiv 2021

An insertion unique to SARS-CoV-2 exhibits super antigenic character strengthened by recent mutations

A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro

Moschüring-Alieva Villalon, G. Multisystem inflammatory syndrome in children (MIS-C): The role of viral superantigens in COVID-19 disease

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Multisystem inflammatory syndrome in children (MISC): A systematic review

Pediatric Inflammatory Multisystem Syndrome Temporally Related With SARS-CoV-2: Immunological Similarities With Acute Rheumatic Fever and Toxic Shock Syndrome

The etiology of Kawasaki disease: A superantigen-mediated process

Symptoms, complications and management of long COVID: A review

Neuropsychiatric symptoms in lupus

Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients

An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life

Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study

Exposure to aerosolized staphylococcal enterotoxin B potentiated by lipopolysaccharide modifies lung transcriptomes and results in lung injury in the mouse model

Intestinal Barrier Function in Health and Disease-Any role of SARS-CoV-2? Microorganisms 2020, 8, 1744

Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development

New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness

Persistence of intestinal SARS-CoV-2 infection in patients with COVID-19 leads to re-admission after pneumonia resolved

Chronic SARS-CoV-2, a Cause of Post-acute COVID-19 Sequelae (Long-COVID)? Front. Microbiol

SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance

Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID-19 patients

Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation

The ancient and the new": Is there an interaction between cytomegalovirus and SARS-CoV-2 infection?

Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective

An Epstein-Barr virus-associated superantigen

Enhanced HIV-1 replication in Vβ12 T cells due to human cytomegalovirus in monocytes: Evidence for a putative herpesvirus superantigen

Virus-encoded superantigens

Covid-19: An urgent call for global "vaccines-plus" action

Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality

Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years-United States

Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months

Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection

Evolutionary trajectory of SARS-CoV-2 and emerging variants

COVID-19) Infection in the UK

Impact of Sex on Systemic Lupus Erythematosus-Related Causes of Premature Mortality in the United States

Kawasaki disease, autoimmune disorders, and cancer: A register-based study

Ten scientific reasons in support of airborne transmission of SARS-CoV-2

Uncertainty around the Long-Term Implications of COVID-19

Understanding the Effects of Age and T-Cell Differentiation on COVID-19 Severity: Implicating a Fas/FasL-mediated Feed-Forward Controller of T-Cell Differentiation. Front

Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations